LONDON, United Kingdom — March 17, 2026. LabGenius Therapeutics (“LabGenius”), a drug discovery company combining artificial intelligence (AI), high-throughput experimentation and machine-learning to discover next-generation therapeutic antibodies, today announced that a scientific poster will be presented at the AACR Annual Meeting 2026, being held April 17–22, 2026, at the San Diego Convention Center, California.
The poster will debut preclinical data for LGTX-101, the company’s selectivity-enhanced Nectin-4 x CD3 T-cell engager (TCE), demonstrating:
- A preliminary pharmacokinetic profile that supports the potential for a Q2W–Q4W clinical dosing regimen
- Robust T-cell activation in primary bladder cancer co-culture models at concentrations below 5 pM
- No evidence of T-cell activation when peripheral blood mononuclear cells (PBMCs) are cultured with human primary keratinocytes, which are known to endogenously express Nectin-4
- Robust and reproducible regression of established tumours in vivo in a humanised BT-474 xenograft mouse model with >90% tumour growth inhibition observed at dose levels as low as 0.1 mg/kg
Poster Presentation Details
| Title | A Novel Machine-Learning Derived Nectin-4 x CD3 Bispecific T-Cell Engager, LGTX-101, Demonstrates High Degrees of Tumour Selectivity and Potently Induces Tumour Regression in vivo |
| Date and time | Monday, April 20, 2026, 09:00–12:00 (PDT) |
| Poster details | Number 1626 | Section 10 | Board 18 |
| Location | San Diego Convention Center, California |
LGTX-101 Overview
LabGenius has developed LGTX-101, a selectivity-enhanced Nectin-4 x CD3 T-cell engager (TCE). The company’s lead optimisation platform, EVA™,was used to discover and optimise a TCE for improved killing selectivity, potency, efficacy, and manufacturability. The biological mechanism underlying this enhanced selectivity is based on the principle of avidity. By harnessing avidity-driven selectivity, the optimised LGTX-101 can distinguish between healthy and diseased cells based on differential tumour-associated antigen expression.
About LabGenius Therapeutics
LabGenius Therapeutics (“LabGenius”) is a drug discovery company pioneering the discovery of next-generation therapeutic antibodies. The company’s discovery platform, EVA™, integrates several cutting-edge technologies drawn from the fields of artificial intelligence, robotic automation and synthetic biology. LabGenius operates a hybrid business model that includes partnering with biotech and pharmaceutical companies in parallel with pursuing a wholly-owned therapeutic pipeline. For more information, please visit www.labgeniustx.com, or connect on LinkedIn.
Contacts
Media: press@labgeni.us
Corporate / business development: partnerships@labgeni.us
